The NLRP3 inflammasome has long been one of immunology’s most consequential and most guarded molecular machines. Sitting inside macrophages and monocytes, this multi-protein complex acts as a tripwire for cellular danger, responding to an astonishingly diverse array of threats ranging from bacterial toxins and extracellular ATP to silica crystals and uric acid deposits. When triggered, NLRP3 assembles into a large signaling platform that activates caspase-1, driving the maturation and release of the potent inflammatory cytokines interleukin-1β and interleukin-18, and ultimately igniting a form of inflammatory cell death called pyroptosis. Yet for all that is known about what NLRP3 does, a central question has stubbornly persisted: how does the protein actually switch itself on? Now, a study published in Nature Immunology by Minghui Pan, Jie Zhou, Shuo Fu, Yuluan Tang, Gonglu Zou, Pilong Li, Zhengfan Jiang and colleagues at Peking University and Tsinghua University provides a striking answer, identifying the autophagy-associated protein AMBRA1 as the long-sought molecular key that releases NLRP3 from its self-imposed lockdown.
The significance of the finding lies in the peculiar architecture of NLRP3 itself. Like other members of the NOD-like receptor family, NLRP3 is built from a pyrin domain at its amino terminus, a central NACHT nucleotide-binding domain, helical domain 2, and a carboxy-terminal leucine-rich repeat region. Structural work over the past several years, including cryo-electron microscopy studies of full-length NLRP3, has revealed that in its resting state the protein folds back on itself into a compact, ADP-bound, cage-like conformation. The leucine-rich repeats wrap around the NACHT domain, and multiple intramolecular contacts lock the receptor into an autoinhibited state. This autorepression is essential for preventing spurious inflammation, but it also creates a puzzle: activating stimuli as chemically and physically diverse as nigericin, ATP, crystalline silica and imiquimod do not bind NLRP3 directly. Something else inside the cell must physically pry the receptor open, and until now, that something had not been convincingly identified.
To find it, the team took an unbiased approach. Using two complementary screening strategies, including mass spectrometry of ASC immunoprecipitates and insoluble complexes isolated from activated immune cells, they searched for proteins that associate with the NLRP3 inflammasome during activation. Among the hits that emerged was AMBRA1, short for activating molecule in Beclin1-regulated autophagy protein 1. AMBRA1 was already a familiar name in cell biology, having first been characterized as a regulator of autophagy and nervous system development, and more recently implicated in the control of D-type cyclins through cullin-RING ubiquitin ligase complexes. Its appearance in the NLRP3 proteome suggested an entirely unexpected second career for the protein. The researchers confirmed that AMBRA1 is a genuine constituent of the NLRP3 inflammasome complex, co-localizing with NLRP3 and ASC specks in stimulated cells.
The functional evidence was immediate and compelling. When the researchers deleted AMBRA1 from human THP-1 monocytic cells or from murine immortalized bone marrow-derived macrophages, NLRP3 activation collapsed. Cells lacking AMBRA1 failed to form ASC specks efficiently, showed reduced cleavage of caspase-1 and gasdermin D, and secreted far less interleukin-1β in response to nigericin, ATP and silica dioxide. Importantly, the defect was selective. Activation of the related NLRP1 inflammasome, triggered by the drug Val-boroPro, and AIM2 inflammasome activation induced by cytosolic DNA via poly(dA:dT) proceeded normally in AMBRA1-deficient cells, indicating that AMBRA1 is not a general requirement for inflammasome assembly but a specific cofactor for NLRP3. Reconstituting the knockout cells with full-length AMBRA1 restored inflammasome activity, cementing the causal relationship.
Delving into mechanism, the team demonstrated that AMBRA1 acts through direct physical binding to NLRP3. Using a combination of co-immunoprecipitation, in vitro protein interaction assays and fluorescence lifetime imaging microscopy-based Förster resonance energy transfer, they showed that AMBRA1 engages two specific subdomains of NLRP3: the leucine-rich repeat region and helical domain 2. The AMBRA1 surface responsible for this engagement involves its β-propeller domain together with an N-terminal helical region. Structural modeling, informed by AlphaFold 3-based predictions and supported by biochemical validation, revealed a large interaction interface burying roughly 3900 square angstroms of surface area, with the AMBRA1 β-propeller and N-terminal helix inserting into the concave face of the NACHT-LRR region of NLRP3.
The allosteric consequences of this binding are the heart of the discovery. By comparing structural models of AMBRA1-bound NLRP3 with the established inactive conformation, the researchers found that AMBRA1 engagement destabilizes the intertwined LRR assembly and promotes detachment of the interlocked NACHT subdomains. In other words, AMBRA1 physically pries apart the contacts that hold NLRP3 in its closed, ADP-bound, autoinhibited cage. Once the receptor is loosened, the nucleotide-binding pocket becomes accessible, and the team showed that AMBRA1 facilitates the binding of ATP to NLRP3. Nucleotide exchange and hydrolysis then drive the global conformational rearrangement that exposes oligomerization interfaces and the pyrin domain, allowing NLRP3 to multimerize, recruit the adaptor ASC, and launch the caspase-1 cascade. The authors draw an instructive parallel to Apaf-1, the apoptosome scaffold, which is likewise held inactive by an intramolecular interaction between its amino-terminal region and a WD40 β-propeller and is opened by binding of cytochrome c between its propellers. AMBRA1, in this scheme, plays a role for NLRP3 conceptually analogous to that of cytochrome c for Apaf-1, a conserved strategy of scaffold-mediated release from autoinhibition.
The study also clarified how AMBRA1 fits into the established, multistep model of NLRP3 activation. Prior work from the same collaborative group had shown that signal-induced phase separation of NLRP3 initiates inflammasome assembly, and other laboratories had defined roles for NEK7 licensing, trans-Golgi recruitment via phosphatidylinositol-4-phosphate, palmitoylation by ZDHHC enzymes, and deubiquitination by BRCC3. The new data indicate that AMBRA1 operates at the conformational opening step, acting as a scaffold that both promotes NLRP3 condensation and oligomerization and enables the transition to the ATP-bound active state. Genetic experiments showed that AMBRA1 deficiency did not disrupt upstream events such as priming of NF-κB signaling, dispersal of the trans-Golgi network, or lysosomal damage, pinpointing its action squarely at the level of NLRP3 itself. Notably, the interaction between AMBRA1 and NLRP3 was unaffected by the clinical-stage NLRP3 inhibitor MCC950, suggesting the two regulatory mechanisms are distinct.
The physiological stakes were tested in mouse models. Myeloid-cell-specific AMBRA1 knockout mice, generated using a Lyz2-Cre driver, showed markedly reduced inflammatory responses in three preclinical settings: endotoxic shock induced by lipopolysaccharide, dextran sulfate sodium-induced colitis, and polymicrobial sepsis. In the colitis model, animals lacking AMBRA1 in myeloid cells were protected from the weight loss and colon shortening that characterize the disease, phenocopying the protection seen in Nlrp3-deficient mice. These results position AMBRA1 as a genuine driver of NLRP3-dependent pathology in vivo, not merely a biochemical curiosity.
Perhaps the most translationally exciting aspect of the work is therapeutic. The team screened nanobodies, the single-domain antibodies derived from camelids, against AMBRA1 using a yeast surface display platform. Several nanobodies targeting the N-terminal helical region of AMBRA1, including Nb27, Nb14 and Nb35, blocked the AMBRA1-NLRP3 interaction and potently inhibited NLRP3 activation and interleukin-1β release in response to nigericin and to Salmonella typhimurium infection. Because the interface is a defined protein-protein contact rather than an enzymatic active site, it offers a structurally characterized target for small molecules or engineered biologics aimed at taming NLRP3-driven inflammation. Given the involvement of this inflammasome in gout, atherosclerosis, type 2 diabetes, Alzheimer’s disease, inflammatory bowel disease and sepsis, a validated molecular switch at the heart of NLRP3 activation could reshape the search for next-generation anti-inflammatory drugs.
The discovery also reframes AMBRA1 itself. A protein celebrated for coordinating autophagy initiation, dynein-dependent trafficking of autophagosomes and cyclin D degradation now stands revealed as a bifunctional regulator straddling two of the cell’s most fundamental stress responses: self-digestion and inflammation. How cells coordinate AMBRA1’s commitments between these pathways, and whether autophagy-related post-translational modifications tune its inflammasome-scaffolding activity, are questions the field will now pursue. What is already clear is that the autoinhibited cage of NLRP3 has a lock, and the key has finally been found.
Subject of Research: Allosteric activation of the NLRP3 inflammasome by the autophagy adaptor protein AMBRA1
Article Title: AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition
Article References: Pan, M., Zhou, J., Fu, S., Tang, Y., Zou, G., Li, P., & Jiang, Z. (2026). AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition. Nature Immunology. https://doi.org/10.1038/s41590-026-02644-x
Image Credits: AI Generated
DOI: 10.1038/s41590-026-02644-x
Keywords: NLRP3, AMBRA1, inflammasome, innate immunity, allosteric activation, autoinhibition, interleukin-1β, pyroptosis, autophagy, nanobodies, inflammation, sepsis
Cite Scienmag News
APA MLA Chicago
Kristina Jarvis. (September 12, 2026). Autophagy Protein AMBRA1 Unlocks NLRP3 Inflammasome Activation. Scienmag. https://scienmag.com/autophagy-protein-ambra1-unlocks-nlrp3-inflammasome-activation/
Kristina Jarvis. “Autophagy Protein AMBRA1 Unlocks NLRP3 Inflammasome Activation.” Scienmag, 12 September 2026, https://scienmag.com/autophagy-protein-ambra1-unlocks-nlrp3-inflammasome-activation/. Accessed 12 September 2026.
Kristina Jarvis. “Autophagy Protein AMBRA1 Unlocks NLRP3 Inflammasome Activation.” Scienmag. September 12, 2026. https://scienmag.com/autophagy-protein-ambra1-unlocks-nlrp3-inflammasome-activation/
Copy citation Download RIS
Tags: allosteric activationAMBRA1autoinhibitionautophagyautophagy and immune regulationautophagy protein AMBRA1cell danger sensing pathwaysinflammasomeinflammasome assembly processinflammationinflammatory cytokine maturationinnate immune responseinnate immunityinterleukin-1βmacrophage molecular signalingmolecular mechanisms of NLRP3 activationnanobodiesNLRP3NLRP3 inflammasome activationNLRP3 self-regulationpyroptosispyroptosis mechanismrole of AMBRA1 in inflammationsepsis
